Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of ZS in Japanese Subjects With Hyperkalemia
NCT03172702Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2017
- Primary completion
- Jul 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of sodium zirconium cyclosilicate in hyperkalemia, sponsored by AstraZeneca. Started Sep 2017; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT03172702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03172702.